2017 Publications
  1. Georgoff PE, Nikolian VC, Bonham T, Pai MP, Tafatia C, Halaweish I, To K, Watcharotone K, Parameswaran A, Luo R, Sun D, Alam HB. Safety and tolerability of intravenous valproic acid in healthy subjects: A phase 1 dose-escalation trial. Clin Pharmacokinet. 2017 May 11. [Epub ahead of print]. PMID: 28497259
  2. Zhao Y, Bai L, Liu L, McEachern D, Stuckety JA, Meagher JL, Yang CY, Ran X, Zhou B, Hu Y, Li X, Wen B, Zhao T, Li S, Sun D, Wang S. Structure-based discovery of 4-(6-methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a potent and orally bioavailable BET bromodomain inhibitor. J Med Chem. 2017 May 11;60(9):3887-3901. PMID: 28463487
  3. Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher JL, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S. Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res. 2017 May 1; 77(9):2476-2487. PMID: 28209615
  4. Zhao Y, Bai L, Liu L, McEachern D, Stuckety JA, Meagher JL, Yang CY, Ran X, Zhou B, Hu Y, Li X, Wen B, Zhao T, Li S, Sun D, Wang S. Structure-based discovery of 4-(6-methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a potent and orally bioavailable BET bromodomain inhibitor. J Med Chem. 2017 May 11;60(9):3887-3901. PMID: 28463487
  5. Georgoff PE, Nikolian VC, Bonham T, Pai MP, Tafatia C, Halaweish I, To K, Watcharotone K, Parameswaran A, Luo R, Sun D, Alam HB. Safety and tolerability of intravenous valproic acid in healthy subjects: A phase 1 dose-escalation trial. Clin Pharmacokinet. 2017 May 11. [Epub ahead of print]. PMID: 28497259
  6. Hutchings KM, Lisabeth EM, Rajeswaran W, Wilson MW, Sorenson RJ, Campbell PL, Ruth JH, Amin A, Tsou PS, Leipprandt JP, Olson SR, Wen B, Zhao T, Sun D, Khanna D, Fox DA, Neubig RR, Larsen SD. Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1744-1749. PMCID: PMC5395305
  7. Aguilar A, Lu J, Liu L, Du D, Bernard D, McEachern D, Przybranowski S, Li X, Luo R, Wen B, Sun D, Wang H, Wen J, Wang G, Zhai Y, Guo M, Yang D, Wang S. Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development. J Med Chem. 2017 Apr 13;60(7):2819-2839. PMCID: PMC5394527
  8. Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang CY, Zhao Y, McEachern D, Przybranowski S, Wen B, Sun D, Wang S. Discovery of a small-molecule degrader of Bromodomain and Extra-Terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J Med Chem. 2017 Mar 24. [Epub ahead of print] PMID: 28339196 
  9. Patel TS, Cinti S, Sun D, Li S, Luo R, Wen B, Gallagher BA, Stevenson JG. Oseltamivir for pandemic influenza preparation: Maximizing the use of an existing stockpile. Am J Infect Control. 2017 Mar 1;45(3):303-305. PMID: 27816215
  10. Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher JL, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S. Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res. 2017 May 1; 77(9):2476-2487. PMID: 28209615
  11. Luo R, LI Y, He M, Zhang H, Yuan H, Johnson M, Palmisano M, Zhou S, Sun D. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations. Int J Pharm. 2017 Jan 4;519(1-2):1-10. PMID: 28063903
  12. Wagner D, Caraballo M, Waldvogel J, Peterson Y, Sun D. In vitro effects of an extracorporeal membrane oxygenation circuit on the sequestration of ϵ-aminocaproic acid. Perfusion. 2017 Apr;32(3):226-229. PMID: 27815558
2016 Publications
  1. Borkin D, Pollock J, Kempinska K, Purohit T, Li X, Wen B, Zhao T, Miao H, Shukla S, He M, Sun D, Cierpicki T, Grembecka J. Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein–Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). J Med Chem. 2016. PMID: 26744767
  2. Connarn JN, Luo R, Windak J, Zhang X, Babiskin A, Kelly M, Harrington G, Ellingrod VL, Kamali M, McInnis M, and Sun D. Identification of non-reported bupropion metabolites in human plasma. Biopharm Drug Disposition. 2016 Dec;37(9):550-560. PMCID: PMC5132048.
  3. Zhang H, Lauver DA, Wang H, Sun D, Hollenberg PF, Chen YE, Osawa Y, Eitzman DT. Significant improvement of antithrombotic responses to clopidogrel by use of a novel conjugate as revealed in an arterial model of thrombosis. J Pharmacol Exp Ther. 2016 Oct;359(1):11-7. PMCID: PMC5034710
  4. Costa MD, Ashraf NS, Fischer S, Yang Y, Schapka E, Joshi G, McQuade TJ, Dharia RM, Dulchavsky M, Ouyang M, Cook D, Sun D, Larsen MJ, Gestwicki JE, Todi SV, Ivanova MI, Paulson HL. Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3. Brain. 2016 Sept 19 [Epub ahead of print] PMID: 27645800
  5. Passalacqua KD, Charbonneau ME, Donato N, Showalter H, Sun D, Wen B, He M, Sun H, O'Riordan M, Wobu C. Anti-infective activity of 2-cyano-3-acrylamide inhibitors with improved drug-like properties against two intracellular pathogens. American Society for Microbiology. 2016 Jul;60(7):4183-96. PMID: 27139470
  6. Borkin D, Pollock JW, Kempinska K, Purohit T, Li X, Wen B, Zhao T, Miao H, Shukla S, He M, Sun D, Cierpicki T, Grembecka J. Property focused structure-based optimization of small molecule inhibitors of the protein-protein interaction between Menin and Mixed Lineage Leukemia (MLL). J Med Chem. 2016 Feb 11;59(3):892-913. PMCID: PMC5092235 
2015 Publications
  1. Peterson LF, Sun HS, Liu YH, Potu H, Kandarpa M, Ermann M, Courtney SM, Young M, Showalter HD, Sun DX, Jakubowiak A, Malek SN, Talpaz M, Donato NJ. Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. Blood. 2015;125(23):3588-97. PMID: 25814533
  2. Friese, CR, Mendelsohn-Victor K, Wen B, Sun D, Sutcliffe K, Yang JJ, Ronis DL, McCullagh MC, DEFENS Study investigators. DEFENS - Drug Exposure Feedback and Education for Nurses' Safety: study protocol for a randomized controlled trial. Trials. 2015 Apr 17;16:171. PMCID: PMC4411718
  3. Connarn JN, Zhang X, Babiskin A, Sun D. Metabolism of bupropion by carbonyl reductases in liver and intestine. Drug Metab Dispos. 2015;43(7):1019-27. PMID: 25904761
  4. Brooks AF, Jackson IM, Shao X, Kropog GW, Sherman P, Quesada CA, Scott PJH. Synthesis and evaluation of [11C]PBD150, a radiolabeled glutaminyl cyclase inhibitor for the potential detection of Alzheimer's disease prior to amyloid [small beta] aggregation. MedChemComm. 2015;6(6):1065-8. PMCID: PMC4474278
  5. Borkin D, He SH, Miao HZ, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang JY, Wen B, Zong HL, Jones M, Danet-Desnoyers G, Guzman ML, Talpaz M, Bixby DL, Sun DX, Hess JL, Muntean AG, Maillard I, Cierpicki T, Grembecka J. Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo. Cancer Cell. 2015;27(4):589-602. PMCID: PMC4415852
  6. Friese CR, McArdle C, Zhao T, Sun D, Spasojevic I, Polovich M, McCullagh MC. Antineoplastic Drug Exposure in an Ambulatory Setting: A Pilot Study. Cancer Nurs. 2015 Mar-Apr;38(2):111-7. PMCID: PMC4232489
2014 Publications
  1. Larsen MJ, Larsen SD, Fribley A, Grembecka J, Homan K, Mapp A, Haak A, Nikolovska-Coleska Z, Stuckey JA, Sun DX, Sherman DH. The Role of HTS in Drug Discovery at the University of Michigan. Comb Chem High T Scr. 2014;17(3):210-30. PMCID: PMC4166557
  2. Kintzel PE, Zhao T, Wen B, Sun D. Stability of i.v. admixture containing metoclopramide, diphenhydramine hydrochloride, and dexamethasone sodium phosphate in 0.9% sodium chloride injection. Am J Health Syst Pharm. 2014 Dec 1;71(23):2061-5. PMID: 25404598
  3. Chen J, Jiang C, Levant B, Li X, Zhao T, Wen B, Luo R, Sun D, Wang S. Pramipexole Derivatives as Potent and Selective Dopamine D-3 Receptor Agonists with Improved Human Microsomal Stability. ChemMedChem. 2014;9(12):2653-60. PMCID: PMC4277207
  4. Abulwerdi F, Liao C, Liu M, Azmi AS, Aboukameel A, Mady AS, Gulappa T, Cierpicki T, Owens S, Zhang T, Sun D, Stuckey JA, Mohammad RM, Nikolovska-Coleska Z. A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In vitro and In vivo. Mol Cancer Ther. 2014 Mar;13(3):565-75. PMCID: PMC4174574
2013 Publications
  1. Zhao Y, Yu S, Sun W, Liu L, Lu J, McEachern D, Shargary S, Bernard D, Li X, Zhao T, Zou P, Sun D, Wang S. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J Med Chem. 2013 Jul 11;56(13):5553-61. PMCID: PMC3880646
  2. Zhao Y, Liu L, Sun W, Lu J, McEachern D, Li X, Yu S, Bernard D, Ochsenbein P, Ferey V, Carry JC, Deschamps JR, Sun D, Wang S. Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. J Am Chem Soc. 2013;135(19):7223-34. PMCID: PMC3806051
  3. Tao Zhang, Yanyan Li, Peng Zou, Jing-yu Yu, Donna McEachern, Shaomeng Wang, and Duxin Sun. Physiologically based pharmacokinetic and pharmacodynamics modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer. Biopharmaceutics & Drug Disposition. 2013. 34:348-59. PMID: 23813446
  4. Zeller J, Turbiak AJ, Powelson IA, Lee S, Sun D, Showalter HD, Fearon ER. Investigation of 3-aryl-pyrimido[5,4-e][1,2,4]triazine-5,7-diones as small molecule antagonists of beta-catenin/TCF transcription. Bioorg Med Chem Lett. 2013;23(21):5814-20. PMCID: PMC3896216
  5. Yestrepsky BD, Xu Y, Breen ME, Li X, Rajeswaran WG, Ryu JG, Sorenson RJ, Tsume Y, Wilson MW, Zhang W, Sun D, Sun H, Larsen SD. Novel inhibitors of bacterial virulence: development of 5,6-dihydrobenzo[h]quinazolin-4(3H)-ones for the inhibition of group A streptococcal streptokinase expression. Bioorg med Chem. 2013;21(7):1880-97. PMCID: PMC3605901
  6. Miyata Y, Li X, Lee HF, Jinwal UK, Srinivasan SR, Seguin SP, Young ZT, Brodsky JL, Dickey CA, Sun D, Gestwicki JE. Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. ACS Chem Neurosci. 2013;4(6):930-9. PMCID: PMC3689201.
  7. Li Y, Zhang T, Li X, Zou P, Schwartz SJ, Sun D. Kinetics of sulforaphane in mice after consumption of sulforaphane-enriched broccoli sprout preparation. Mol Nutr Food Res. 2013 Dec;57(12):2128-36. PMCID: PMC3855579
  8. Li X, Srinivasan SR, Connarn J, Ahmad A, Young ZT, Kabza AM, Zuiderweg ER, Sun D, Gestwicki JE. Analogues of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, As Anti-Cancer Agents. ACS Med Chem Lett. 2013;4(11):1042-7. PMCID: PMC3845967
2012 Publications
  1. Zou P, Zheng N, Yu Y, Yu S, Sun W, McEachem D, Yang Y, Yu LX, Wang S, Sun D. Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics. J Pharm Pharm Sci. 2012;15(2):265-80. PMID: 22579006
  2. Zou P, Zheng N, Yang Y, Yu LX, Sun D. Prediction of Volume of Distribution at Steady-State in Humans: Comparison of Different Approaches. Expert Opinion on Drug Metabolism and Toxicology. 2012;8(7): 855-872 PMID: 22591253
  3. Zou P, Yu Y, Zheng N, Yang Y, Paholak HJ, Yu LX, Sun D. Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation. AAPS J. 2012;14:262-81. PMCID: PMC3326168
2011 Publications
  1. Yu Y, Zick S, Li X, Zou P, Wright B, Sun D. Examination of the Pharmacokinetics of Active Ingredients of Ginger in Humans. AAPS J. 2011, 13(3): 417-26. PMCID: PMC3160151
  2. Sun H, Liu L, Lu J, Bai L, Li X, Nikolovska-Coleska Z, McEachern D, Yang CY, Qiu S, Yi H, Sun D, Wang S. Potent Bivalent Smac Mimetics: Effect of the Linker on Binding to Inhibitor of Apoptosis Proteins (IAPs) and Anticancer Activity. J Med Chem. 2011;54:3306. PMCID: PMC3108148
  3. Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, Liu L, Qiu S, Yang CY, Miller R, Yi H, Zhang T, Sun D, Kang S, Guo M, Leopold L, Yang D, Wang S. A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment. J Med Chem. 2011;54:2714. PMCID: PMC3520070
  4. Zheng N, Zou P, Wang S, Sun D. In Vitro Metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) in Human Liver Microsomes. Drug Metab Dispos. 2011;39:627-35. PMCID: PMC3063720
Previous Publications
  1. Yanke Yu, Lanyan Fang, Duxin Sun. Biodistribution of HuCC49∆CH2-β-galactosidase in colorectal cancer xenograft model. International J Pharmaceutics. 2010, 386: 208. PMCID: PMC2815147
  2. Zou P, Povoski SP, Hall NC, Carlton MM, Hinkle GH, Xu RX, Mozisik CM, Johnson MA, Knopp MV, Martin EW Jr., Sun D. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results. World Journal of Surgical Oncology. 2010;8:65. PMCID: PMC2924340
  3. Zou P, Xu S, Povoski SP, Wang A, Johnson MA, Martin EW, Jr., Subramaniam V, Xu R, Sun D. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol Pharm. 2009;6:428-40. PMCID: PMC2888669.
  4. Fang L, Sun D. Predictive physiological based pharmacokinetic (PBPK) analysis for antibody directed enzyme prodrug therapy (ADEPT). Drug Metab and Dispos. 2008;36:1153-65. PMID: 18356268
  5. Fang L, Holford NH, Hinkle G, Cao X, Bloomston MP, Xiao JJ, Gibbs S, Al Saif OH, Dalton JT, Chan KK, Schlom J, Martin EW, Jr., and Sun D. Population Pharmacokinetics of Humanized Monoclonal Antibody HuCC49∆CH2 and Murine Antibody CC49 in Colorectal Cancer Patients. J Clin Pharmacol. 2007;47(2):227-37. PMID: 17244774
  6. Xianhua Cao, Seth T. Gibbs, Lanyan Fang, Heather A. Miller, Christopher P. Landowski, Ho-Chul Shin, Hans Lennernas, Yanqiang Zhong, Gordon L. Amidon, Lawrence X. Yu, and Duxin Sun. Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model. Pharm Res. 2006, 23: 1675
  7. Badawy SI, Gray DB, Zhao F, Sun D, Schuster AE, Hussain MA. Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389. Pharm Res 2006;23(5):989-96. PMID: 16715389. 
  8. Rong Zhou, Paul Moench, Christopher Heran, Xujin Lu, Neil Mathias, Teresa Faria, Doris A. Wall, Munir A. Hussain, Ronald L. Smith, and Duxin Sun. pH-Dependent Dissolution In Vitro and Absorption In Vivo of Weakly Basic Drugs: Development of a Canine Model. Pharmaceutical Research. 2005, 22: 188
  9. Jim Xiao, Sara Horst, George Hinkle, Xianhua Cao, Ergun Kocak, Jing Fang, Donn Young, M. Khazaeli, Doreen Agnese, Duxin Sun, Edward Martin, Jr. Pharmacokinetics and Clinical Evaluation of 125I-Radiolabeled Humanized CC49 Monoclonal Antibody (HuCC49deltaCH2) in Recurrent and Metastatic Colorectal Cancer Patients. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20: 16
  10. Xianhua Cao, Lawrence X. Yu, Catalin Barbaciru, Christopher P. Landowski, Ho-Chul Shin, Seth Gibbs, Heather A. Miller, Gordon L. Amidon, and Duxin Sun. Permeability Dominates In Vivo Intestinal Absorption of P-gp Substrate with High Solubility and High Permeability. Molecular Pharmaceutics. 2005, 2: 329-340
  11. Sun D, Yu LX, M. Hussain, RL Smith, Amidon GL, and Smith RL. In Vitro Testing of Drug Absorption for Drug “Developability” Assessment: Forming an Interface Between In Vitro Preclinical Data and Clinical Outcome. Current Opinion in Drug Discovery and Development. 2004, 7 (1): 75-85

Posters en route to Publication:

Clinical Pharmacokinetics

  1. Randomized controlled trial to improve oncology nurses’ protective equipment use. CDC R01 OH010582-01, PI: Christopher Friese, Co-I Duxin Sun. 2014-2018. 
  2. Modernization of in vivo-in vitro oral bioperformance prediction and assessment. FDA HHSF223201310144C, Co-PI: Gordon Amidon, Co-PI: Duxin Sun. 2013-2017.
  3. Investigation of release profiles of bupropion and pharmacogenomics of metabolism enzymes for bioequivalance of generic bupropion products in healthy volunteers. FDA HHSF223201310144C, PI: Duxin Sun. 2013-2016.
  4. Correlation of mesalamine pharmacokinetics with local availability. FDA HHSF223201000082C, HHSF223201300460A, PI: Duxin Sun. 2010-2015.

Preclinical Pharmacokinetics

  1. Pharmacokinetics and tissue distribution of Abraxane. Celgene Corporation, PI: Duxin Sun. 2016-2017
  2. Drug tumor distribution impacts efficacy of tamoxifen analogs. Celgene Corporation, PI: Duxin Sun. 2015-2017.
  3. Wireless Pharmaceutical Analysis Device (WPAD) and computation model to determine in vivo drug dissolution in GI tract for distinguishing meaningful product differences and ensuring bioequivalence (BE). FDA HHSF223201510146C, PI: Duxin Sun.
  4. The development of small molecule inhibitors for Gaucher Disease Type 3. NIH UH2-NS-092981-01, PI: James Shayman, Co-I: Duxin Sun. 2015-2016. 
  5. ROS-targeted therapy for pancreatic cancer. NIH R01-CA-188252-01-A1, PI: Nouri Neamati, Co-I: Duxin Sun. 2015-2020. 
  6. Efficacy of PDI inhibitors in glioblastoma. NIH R01 CA193690-01, PI: Nouri Neamati, Co-I: Duxin Sun. 2015-2020. 
  7. Menin-MLL inhibitor program. Kura Oncology, PI: Jolanta Grembecka, Co-I: Duxin Sun. 2015-2018.
  8. SPORE in prostate cancer.  NIH 1P50CA186786-01, PI: Arul Chinnaiyan, Co-I: Duxin Sun. 2014-2019. 
  9. Targeting host deubiquitinases for broad spectrum anti-infective therapy. NIH R21/R33 AI102106-03, PI: Mary O’Riordan, Co-I: Duxin Sun. 2014-2017. 
  10. Enhanced oral delivery of low solubility drugs using cocrystal design. NIH R01 GM107146-01-A1, PI: Nair Rodriguez-Hornedo, Co-I: Duxin Sun. 2014-2018.
  11. Inhibition of the Rho/MRTF/SRF pathway as a new treatment for systemic sclerosis. NIH R01 AR066049, PI: Scott D Larsen, Co-I: Duxin Sun. 2014-2017. 
  12. Discovering Novel Atypical PKC Inhibitors as in vivo Chemical Probes. NIH R01 EY023725, PI: David Antonetti, Co-I: Duxin Sun. 2014-2017. 
  13. Define and optimize tumor targeting properties to predict preclinical and clinical efficacy of anti-cnacer agents. Celgene Corporation, PI: Duxin Sun. 2014-2016.
  14. Pharmacokinetics and tumor distribution of different liposomal doxorubicin formulations. Celgene Corporation, PI: Duxin Sun. 2014-2015.
  15. BET Bromodomain Inhibitors. Oncofusion Therapeutics, 145038, PI: Shaomeng Wang, Co-I: Duxin Sun. 2014-2015. 
  16. Targeted elimination of cancer stem cells for AML therapy. NIH R01 CA171972-01A1, PI: Yang Liu, Co-I: Duxin Sun. 2013-2018. 
  17. Targeting the MLL-WDR5 protein-protein interaction. NIH R01 CA177307-01, PI: Shaomeng Wang, Yali Dou, Co-I: Duxin Sun. 2013-2017. 
  18. Novel probes for studying treatment of CNS-based lysosomal storage diseases. NIH R01 HD076004-01, PI:  Scott D Larsen, Co-I: Duxin Sun. 2013-2016.  
  19. Investigation of inequivalence of buproprion hydrochloride extended release tablets: In vitro metabolism quantification. FDA HHSF223201310183C, PI: Duxin Sun. 2013-2015.    
  20. Mechanisms of motor neuron toxicity in Kennedy disease. NIH R01 NS055746-06A1, PI: Andrew Lieberman, Co-I: Duxin Sun. 2012-2017. 
  21. Development of novel anti-leukemia agents targeting the menin-MLL interaction. NIH R01 CA160467-01. PI: Jolanta Grembecka, Co-I: Duxin Sun. 2011-2016. 
  22. DUB Inhibitors for Treatment of B-cell Malignancies. Lymphoma and Leukemia Society. PI: Nick Donato, Co-I: Duxin Sun. 2012-2013. 
  23. Potent and Highly Selective D3 Ligands for the Treatment of Cocaine Abuse. NIH R01 DA032943. PI: Shaomeng Wang, Co-I: Duxin Sun. 2012-2016. 
  24. In vivo proof of efficacy studies for a novel glucosylceramide synthase inhibitor with central nervous system activity. NIH R21 NS079633-01, PI: James Shayman, Co-I: Duxin Sun. 2012-2014.
  25. Receptor Na/K-ATPase antagonists as novel therapeutics for renal/cardiac diseases. NIH R01 HL109015-01. PI: ZiJian Xie, Co-I: Duxin Sun. 2011-2015. 
  26. Menin-MLL Fusion Inhibitor Program. Lymphoma and Leukemia Society. UM347450 /N013134-03. PI: Jolanta Grembecka,  Co-I: Duxin Sun. 2010-2015. 
  27. Chaperones and Small Molecules NIH R01 NS059690-S1, PI: Jason Gestwicki, Co-I: Duxin Sun. 2010-2011. 
  1. Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jay L. Hess, Duxin Sun, Xiaoqin Li. Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof.

US patent number 9216693 issued 12/22/2015.

US patent application 14/773,686 filed 9/8/2015. 

US patent application 14/937421 filed 11/10/2015.

  1. Shaomeng Wang, Jianfang Chen, Donna McEachern, Longchuan Bai, Liu Liu, Duxin Sun, Xiaoqin Li, Angelo Aguilar. BCL-2/BCL-XL Inhibitors and therapeutic methods using the same.

US patent number 9096625 issued 7/15/2015.

US patent application 14/816,191 filed 8/3/2015.

  1. Shaomeng Wang, Haibin Zhou, Jianfang Chen, Angelo Aguilar, Jennifer Meagher, Duxin Sun, Chao-Yie Yang, Liu Liu, Longchuan Bai, Donna J. McEachern, Jeanne A. Stuckey-Cupp, Xiaoqin Li. BCL-2/BCL-XL Inhibitors and therapeutic methods using the same.

US patent number 8691184 issued 4/8/2014.

  1. Shaomeng Wang, Shanghai Yu, Wei Sun, Sanjeev Kumar Shangary, Duxin Sun, Peng Zou, Donna McEachern, Yujun Zhao. Spiro-oxindole MDM2 antagonists.

US patent number 9079913 issued 6/24/2015.

US patent number 8877796 issued 11/4/2014.

US patent number 8518984 issued 8/27/2013. 

  1. Ruijuan Luo, Duxin Sun, Jamie Connarn, Vicki L. Ellingrod, Melvin McInnis. Bupropion metabolites and uses thereof

Filed for US provisional patent 3/31/2016.

  1. Scott D. Larsen, Akira Abe, Liming Shu, Michael W. Wilson, Richard F. Keep, Duxin Sun, James A. Shayman. Glycosylceramide synthase inhibitors and therapeutic methods using the same.

Filed for US provisional patent 2015.

  1. Shaomeng Wang, Yujun Zhao, Bing Zhao, Angelo Aguilar, Liu Liu, Longchuan Bai, Donna McEachern, Duxin Sun, Bo Wen, Ruijuan Luo, Ting Zhao, Arul Chinnaiyan, Irfan A. Asangani, Jeanne Stuckey, Jennifer Lynn Meagher, and Xu Ran. 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors.

Filed for US provisional patent 2014; US patent application 14/633,360 filed 2/27/2015.

  1. Shaomeng Wang, Arul Chinnaiyan, Irfan Asangani, Yujun Zhao, Bing Zhou, Liu Liu, Longchuan Bai, Angelo Aguilar, Donna J. McEachern, Xu Ran, Duxin Sun, Chao-Yie Yang, Ruijuan Luo, Jeanne A. Stuckey, Jennifer Meagher, Xiaoqin Li, Bo Wen, Hacer Karatas, Ting Zhao. BET bromodomain inhibitors and therapeutic methods using the same.

PCT patent application PCT/US2014/022953 filed 3/11/2014.

 

Supported Publications
2017 Publications
  1. Georgoff PE, Nikolian VC, Bonham T, Pai MP, Tafatia C, Halaweish I, To K, Watcharotone K, Parameswaran A, Luo R, Sun D, Alam HB. Safety and tolerability of intravenous valproic acid in healthy subjects: A phase 1 dose-escalation trial. Clin Pharmacokinet. 2017 May 11. [Epub ahead of print]. PMID: 28497259
  2. Zhao Y, Bai L, Liu L, McEachern D, Stuckety JA, Meagher JL, Yang CY, Ran X, Zhou B, Hu Y, Li X, Wen B, Zhao T, Li S, Sun D, Wang S. Structure-based discovery of 4-(6-methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a potent and orally bioavailable BET bromodomain inhibitor. J Med Chem. 2017 May 11;60(9):3887-3901. PMID: 28463487
  3. Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher JL, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S. Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res. 2017 May 1; 77(9):2476-2487. PMID: 28209615
  4. Zhao Y, Bai L, Liu L, McEachern D, Stuckety JA, Meagher JL, Yang CY, Ran X, Zhou B, Hu Y, Li X, Wen B, Zhao T, Li S, Sun D, Wang S. Structure-based discovery of 4-(6-methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a potent and orally bioavailable BET bromodomain inhibitor. J Med Chem. 2017 May 11;60(9):3887-3901. PMID: 28463487
  5. Georgoff PE, Nikolian VC, Bonham T, Pai MP, Tafatia C, Halaweish I, To K, Watcharotone K, Parameswaran A, Luo R, Sun D, Alam HB. Safety and tolerability of intravenous valproic acid in healthy subjects: A phase 1 dose-escalation trial. Clin Pharmacokinet. 2017 May 11. [Epub ahead of print]. PMID: 28497259
  6. Hutchings KM, Lisabeth EM, Rajeswaran W, Wilson MW, Sorenson RJ, Campbell PL, Ruth JH, Amin A, Tsou PS, Leipprandt JP, Olson SR, Wen B, Zhao T, Sun D, Khanna D, Fox DA, Neubig RR, Larsen SD. Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1744-1749. PMCID: PMC5395305
  7. Aguilar A, Lu J, Liu L, Du D, Bernard D, McEachern D, Przybranowski S, Li X, Luo R, Wen B, Sun D, Wang H, Wen J, Wang G, Zhai Y, Guo M, Yang D, Wang S. Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development. J Med Chem. 2017 Apr 13;60(7):2819-2839. PMCID: PMC5394527
  8. Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang CY, Zhao Y, McEachern D, Przybranowski S, Wen B, Sun D, Wang S. Discovery of a small-molecule degrader of Bromodomain and Extra-Terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J Med Chem. 2017 Mar 24. [Epub ahead of print] PMID: 28339196 
  9. Patel TS, Cinti S, Sun D, Li S, Luo R, Wen B, Gallagher BA, Stevenson JG. Oseltamivir for pandemic influenza preparation: Maximizing the use of an existing stockpile. Am J Infect Control. 2017 Mar 1;45(3):303-305. PMID: 27816215
  10. Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher JL, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S. Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res. 2017 May 1; 77(9):2476-2487. PMID: 28209615
  11. Luo R, LI Y, He M, Zhang H, Yuan H, Johnson M, Palmisano M, Zhou S, Sun D. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations. Int J Pharm. 2017 Jan 4;519(1-2):1-10. PMID: 28063903
  12. Wagner D, Caraballo M, Waldvogel J, Peterson Y, Sun D. In vitro effects of an extracorporeal membrane oxygenation circuit on the sequestration of ϵ-aminocaproic acid. Perfusion. 2017 Apr;32(3):226-229. PMID: 27815558
2016 Publications
  1. Borkin D, Pollock J, Kempinska K, Purohit T, Li X, Wen B, Zhao T, Miao H, Shukla S, He M, Sun D, Cierpicki T, Grembecka J. Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein–Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). J Med Chem. 2016. PMID: 26744767
  2. Connarn JN, Luo R, Windak J, Zhang X, Babiskin A, Kelly M, Harrington G, Ellingrod VL, Kamali M, McInnis M, and Sun D. Identification of non-reported bupropion metabolites in human plasma. Biopharm Drug Disposition. 2016 Dec;37(9):550-560. PMCID: PMC5132048.
  3. Zhang H, Lauver DA, Wang H, Sun D, Hollenberg PF, Chen YE, Osawa Y, Eitzman DT. Significant improvement of antithrombotic responses to clopidogrel by use of a novel conjugate as revealed in an arterial model of thrombosis. J Pharmacol Exp Ther. 2016 Oct;359(1):11-7. PMCID: PMC5034710
  4. Costa MD, Ashraf NS, Fischer S, Yang Y, Schapka E, Joshi G, McQuade TJ, Dharia RM, Dulchavsky M, Ouyang M, Cook D, Sun D, Larsen MJ, Gestwicki JE, Todi SV, Ivanova MI, Paulson HL. Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3. Brain. 2016 Sept 19 [Epub ahead of print] PMID: 27645800
  5. Passalacqua KD, Charbonneau ME, Donato N, Showalter H, Sun D, Wen B, He M, Sun H, O'Riordan M, Wobu C. Anti-infective activity of 2-cyano-3-acrylamide inhibitors with improved drug-like properties against two intracellular pathogens. American Society for Microbiology. 2016 Jul;60(7):4183-96. PMID: 27139470
  6. Borkin D, Pollock JW, Kempinska K, Purohit T, Li X, Wen B, Zhao T, Miao H, Shukla S, He M, Sun D, Cierpicki T, Grembecka J. Property focused structure-based optimization of small molecule inhibitors of the protein-protein interaction between Menin and Mixed Lineage Leukemia (MLL). J Med Chem. 2016 Feb 11;59(3):892-913. PMCID: PMC5092235 
2015 Publications
  1. Peterson LF, Sun HS, Liu YH, Potu H, Kandarpa M, Ermann M, Courtney SM, Young M, Showalter HD, Sun DX, Jakubowiak A, Malek SN, Talpaz M, Donato NJ. Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. Blood. 2015;125(23):3588-97. PMID: 25814533
  2. Friese, CR, Mendelsohn-Victor K, Wen B, Sun D, Sutcliffe K, Yang JJ, Ronis DL, McCullagh MC, DEFENS Study investigators. DEFENS - Drug Exposure Feedback and Education for Nurses' Safety: study protocol for a randomized controlled trial. Trials. 2015 Apr 17;16:171. PMCID: PMC4411718
  3. Connarn JN, Zhang X, Babiskin A, Sun D. Metabolism of bupropion by carbonyl reductases in liver and intestine. Drug Metab Dispos. 2015;43(7):1019-27. PMID: 25904761
  4. Brooks AF, Jackson IM, Shao X, Kropog GW, Sherman P, Quesada CA, Scott PJH. Synthesis and evaluation of [11C]PBD150, a radiolabeled glutaminyl cyclase inhibitor for the potential detection of Alzheimer's disease prior to amyloid [small beta] aggregation. MedChemComm. 2015;6(6):1065-8. PMCID: PMC4474278
  5. Borkin D, He SH, Miao HZ, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang JY, Wen B, Zong HL, Jones M, Danet-Desnoyers G, Guzman ML, Talpaz M, Bixby DL, Sun DX, Hess JL, Muntean AG, Maillard I, Cierpicki T, Grembecka J. Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo. Cancer Cell. 2015;27(4):589-602. PMCID: PMC4415852
  6. Friese CR, McArdle C, Zhao T, Sun D, Spasojevic I, Polovich M, McCullagh MC. Antineoplastic Drug Exposure in an Ambulatory Setting: A Pilot Study. Cancer Nurs. 2015 Mar-Apr;38(2):111-7. PMCID: PMC4232489
2014 Publications
  1. Larsen MJ, Larsen SD, Fribley A, Grembecka J, Homan K, Mapp A, Haak A, Nikolovska-Coleska Z, Stuckey JA, Sun DX, Sherman DH. The Role of HTS in Drug Discovery at the University of Michigan. Comb Chem High T Scr. 2014;17(3):210-30. PMCID: PMC4166557
  2. Kintzel PE, Zhao T, Wen B, Sun D. Stability of i.v. admixture containing metoclopramide, diphenhydramine hydrochloride, and dexamethasone sodium phosphate in 0.9% sodium chloride injection. Am J Health Syst Pharm. 2014 Dec 1;71(23):2061-5. PMID: 25404598
  3. Chen J, Jiang C, Levant B, Li X, Zhao T, Wen B, Luo R, Sun D, Wang S. Pramipexole Derivatives as Potent and Selective Dopamine D-3 Receptor Agonists with Improved Human Microsomal Stability. ChemMedChem. 2014;9(12):2653-60. PMCID: PMC4277207
  4. Abulwerdi F, Liao C, Liu M, Azmi AS, Aboukameel A, Mady AS, Gulappa T, Cierpicki T, Owens S, Zhang T, Sun D, Stuckey JA, Mohammad RM, Nikolovska-Coleska Z. A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In vitro and In vivo. Mol Cancer Ther. 2014 Mar;13(3):565-75. PMCID: PMC4174574
2013 Publications
  1. Zhao Y, Yu S, Sun W, Liu L, Lu J, McEachern D, Shargary S, Bernard D, Li X, Zhao T, Zou P, Sun D, Wang S. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J Med Chem. 2013 Jul 11;56(13):5553-61. PMCID: PMC3880646
  2. Zhao Y, Liu L, Sun W, Lu J, McEachern D, Li X, Yu S, Bernard D, Ochsenbein P, Ferey V, Carry JC, Deschamps JR, Sun D, Wang S. Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. J Am Chem Soc. 2013;135(19):7223-34. PMCID: PMC3806051
  3. Tao Zhang, Yanyan Li, Peng Zou, Jing-yu Yu, Donna McEachern, Shaomeng Wang, and Duxin Sun. Physiologically based pharmacokinetic and pharmacodynamics modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer. Biopharmaceutics & Drug Disposition. 2013. 34:348-59. PMID: 23813446
  4. Zeller J, Turbiak AJ, Powelson IA, Lee S, Sun D, Showalter HD, Fearon ER. Investigation of 3-aryl-pyrimido[5,4-e][1,2,4]triazine-5,7-diones as small molecule antagonists of beta-catenin/TCF transcription. Bioorg Med Chem Lett. 2013;23(21):5814-20. PMCID: PMC3896216
  5. Yestrepsky BD, Xu Y, Breen ME, Li X, Rajeswaran WG, Ryu JG, Sorenson RJ, Tsume Y, Wilson MW, Zhang W, Sun D, Sun H, Larsen SD. Novel inhibitors of bacterial virulence: development of 5,6-dihydrobenzo[h]quinazolin-4(3H)-ones for the inhibition of group A streptococcal streptokinase expression. Bioorg med Chem. 2013;21(7):1880-97. PMCID: PMC3605901
  6. Miyata Y, Li X, Lee HF, Jinwal UK, Srinivasan SR, Seguin SP, Young ZT, Brodsky JL, Dickey CA, Sun D, Gestwicki JE. Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. ACS Chem Neurosci. 2013;4(6):930-9. PMCID: PMC3689201.
  7. Li Y, Zhang T, Li X, Zou P, Schwartz SJ, Sun D. Kinetics of sulforaphane in mice after consumption of sulforaphane-enriched broccoli sprout preparation. Mol Nutr Food Res. 2013 Dec;57(12):2128-36. PMCID: PMC3855579
  8. Li X, Srinivasan SR, Connarn J, Ahmad A, Young ZT, Kabza AM, Zuiderweg ER, Sun D, Gestwicki JE. Analogues of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, As Anti-Cancer Agents. ACS Med Chem Lett. 2013;4(11):1042-7. PMCID: PMC3845967
2012 Publications
  1. Zou P, Zheng N, Yu Y, Yu S, Sun W, McEachem D, Yang Y, Yu LX, Wang S, Sun D. Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics. J Pharm Pharm Sci. 2012;15(2):265-80. PMID: 22579006
  2. Zou P, Zheng N, Yang Y, Yu LX, Sun D. Prediction of Volume of Distribution at Steady-State in Humans: Comparison of Different Approaches. Expert Opinion on Drug Metabolism and Toxicology. 2012;8(7): 855-872 PMID: 22591253
  3. Zou P, Yu Y, Zheng N, Yang Y, Paholak HJ, Yu LX, Sun D. Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation. AAPS J. 2012;14:262-81. PMCID: PMC3326168
2011 Publications
  1. Yu Y, Zick S, Li X, Zou P, Wright B, Sun D. Examination of the Pharmacokinetics of Active Ingredients of Ginger in Humans. AAPS J. 2011, 13(3): 417-26. PMCID: PMC3160151
  2. Sun H, Liu L, Lu J, Bai L, Li X, Nikolovska-Coleska Z, McEachern D, Yang CY, Qiu S, Yi H, Sun D, Wang S. Potent Bivalent Smac Mimetics: Effect of the Linker on Binding to Inhibitor of Apoptosis Proteins (IAPs) and Anticancer Activity. J Med Chem. 2011;54:3306. PMCID: PMC3108148
  3. Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, Liu L, Qiu S, Yang CY, Miller R, Yi H, Zhang T, Sun D, Kang S, Guo M, Leopold L, Yang D, Wang S. A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment. J Med Chem. 2011;54:2714. PMCID: PMC3520070
  4. Zheng N, Zou P, Wang S, Sun D. In Vitro Metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) in Human Liver Microsomes. Drug Metab Dispos. 2011;39:627-35. PMCID: PMC3063720
Previous Publications
  1. Yanke Yu, Lanyan Fang, Duxin Sun. Biodistribution of HuCC49∆CH2-β-galactosidase in colorectal cancer xenograft model. International J Pharmaceutics. 2010, 386: 208. PMCID: PMC2815147
  2. Zou P, Povoski SP, Hall NC, Carlton MM, Hinkle GH, Xu RX, Mozisik CM, Johnson MA, Knopp MV, Martin EW Jr., Sun D. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results. World Journal of Surgical Oncology. 2010;8:65. PMCID: PMC2924340
  3. Zou P, Xu S, Povoski SP, Wang A, Johnson MA, Martin EW, Jr., Subramaniam V, Xu R, Sun D. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol Pharm. 2009;6:428-40. PMCID: PMC2888669.
  4. Fang L, Sun D. Predictive physiological based pharmacokinetic (PBPK) analysis for antibody directed enzyme prodrug therapy (ADEPT). Drug Metab and Dispos. 2008;36:1153-65. PMID: 18356268
  5. Fang L, Holford NH, Hinkle G, Cao X, Bloomston MP, Xiao JJ, Gibbs S, Al Saif OH, Dalton JT, Chan KK, Schlom J, Martin EW, Jr., and Sun D. Population Pharmacokinetics of Humanized Monoclonal Antibody HuCC49∆CH2 and Murine Antibody CC49 in Colorectal Cancer Patients. J Clin Pharmacol. 2007;47(2):227-37. PMID: 17244774
  6. Xianhua Cao, Seth T. Gibbs, Lanyan Fang, Heather A. Miller, Christopher P. Landowski, Ho-Chul Shin, Hans Lennernas, Yanqiang Zhong, Gordon L. Amidon, Lawrence X. Yu, and Duxin Sun. Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model. Pharm Res. 2006, 23: 1675
  7. Badawy SI, Gray DB, Zhao F, Sun D, Schuster AE, Hussain MA. Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389. Pharm Res 2006;23(5):989-96. PMID: 16715389. 
  8. Rong Zhou, Paul Moench, Christopher Heran, Xujin Lu, Neil Mathias, Teresa Faria, Doris A. Wall, Munir A. Hussain, Ronald L. Smith, and Duxin Sun. pH-Dependent Dissolution In Vitro and Absorption In Vivo of Weakly Basic Drugs: Development of a Canine Model. Pharmaceutical Research. 2005, 22: 188
  9. Jim Xiao, Sara Horst, George Hinkle, Xianhua Cao, Ergun Kocak, Jing Fang, Donn Young, M. Khazaeli, Doreen Agnese, Duxin Sun, Edward Martin, Jr. Pharmacokinetics and Clinical Evaluation of 125I-Radiolabeled Humanized CC49 Monoclonal Antibody (HuCC49deltaCH2) in Recurrent and Metastatic Colorectal Cancer Patients. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20: 16
  10. Xianhua Cao, Lawrence X. Yu, Catalin Barbaciru, Christopher P. Landowski, Ho-Chul Shin, Seth Gibbs, Heather A. Miller, Gordon L. Amidon, and Duxin Sun. Permeability Dominates In Vivo Intestinal Absorption of P-gp Substrate with High Solubility and High Permeability. Molecular Pharmaceutics. 2005, 2: 329-340
  11. Sun D, Yu LX, M. Hussain, RL Smith, Amidon GL, and Smith RL. In Vitro Testing of Drug Absorption for Drug “Developability” Assessment: Forming an Interface Between In Vitro Preclinical Data and Clinical Outcome. Current Opinion in Drug Discovery and Development. 2004, 7 (1): 75-85

Posters en route to Publication:

Supported Grants

Clinical Pharmacokinetics

  1. Randomized controlled trial to improve oncology nurses’ protective equipment use. CDC R01 OH010582-01, PI: Christopher Friese, Co-I Duxin Sun. 2014-2018. 
  2. Modernization of in vivo-in vitro oral bioperformance prediction and assessment. FDA HHSF223201310144C, Co-PI: Gordon Amidon, Co-PI: Duxin Sun. 2013-2017.
  3. Investigation of release profiles of bupropion and pharmacogenomics of metabolism enzymes for bioequivalance of generic bupropion products in healthy volunteers. FDA HHSF223201310144C, PI: Duxin Sun. 2013-2016.
  4. Correlation of mesalamine pharmacokinetics with local availability. FDA HHSF223201000082C, HHSF223201300460A, PI: Duxin Sun. 2010-2015.

Preclinical Pharmacokinetics

  1. Pharmacokinetics and tissue distribution of Abraxane. Celgene Corporation, PI: Duxin Sun. 2016-2017
  2. Drug tumor distribution impacts efficacy of tamoxifen analogs. Celgene Corporation, PI: Duxin Sun. 2015-2017.
  3. Wireless Pharmaceutical Analysis Device (WPAD) and computation model to determine in vivo drug dissolution in GI tract for distinguishing meaningful product differences and ensuring bioequivalence (BE). FDA HHSF223201510146C, PI: Duxin Sun.
  4. The development of small molecule inhibitors for Gaucher Disease Type 3. NIH UH2-NS-092981-01, PI: James Shayman, Co-I: Duxin Sun. 2015-2016. 
  5. ROS-targeted therapy for pancreatic cancer. NIH R01-CA-188252-01-A1, PI: Nouri Neamati, Co-I: Duxin Sun. 2015-2020. 
  6. Efficacy of PDI inhibitors in glioblastoma. NIH R01 CA193690-01, PI: Nouri Neamati, Co-I: Duxin Sun. 2015-2020. 
  7. Menin-MLL inhibitor program. Kura Oncology, PI: Jolanta Grembecka, Co-I: Duxin Sun. 2015-2018.
  8. SPORE in prostate cancer.  NIH 1P50CA186786-01, PI: Arul Chinnaiyan, Co-I: Duxin Sun. 2014-2019. 
  9. Targeting host deubiquitinases for broad spectrum anti-infective therapy. NIH R21/R33 AI102106-03, PI: Mary O’Riordan, Co-I: Duxin Sun. 2014-2017. 
  10. Enhanced oral delivery of low solubility drugs using cocrystal design. NIH R01 GM107146-01-A1, PI: Nair Rodriguez-Hornedo, Co-I: Duxin Sun. 2014-2018.
  11. Inhibition of the Rho/MRTF/SRF pathway as a new treatment for systemic sclerosis. NIH R01 AR066049, PI: Scott D Larsen, Co-I: Duxin Sun. 2014-2017. 
  12. Discovering Novel Atypical PKC Inhibitors as in vivo Chemical Probes. NIH R01 EY023725, PI: David Antonetti, Co-I: Duxin Sun. 2014-2017. 
  13. Define and optimize tumor targeting properties to predict preclinical and clinical efficacy of anti-cnacer agents. Celgene Corporation, PI: Duxin Sun. 2014-2016.
  14. Pharmacokinetics and tumor distribution of different liposomal doxorubicin formulations. Celgene Corporation, PI: Duxin Sun. 2014-2015.
  15. BET Bromodomain Inhibitors. Oncofusion Therapeutics, 145038, PI: Shaomeng Wang, Co-I: Duxin Sun. 2014-2015. 
  16. Targeted elimination of cancer stem cells for AML therapy. NIH R01 CA171972-01A1, PI: Yang Liu, Co-I: Duxin Sun. 2013-2018. 
  17. Targeting the MLL-WDR5 protein-protein interaction. NIH R01 CA177307-01, PI: Shaomeng Wang, Yali Dou, Co-I: Duxin Sun. 2013-2017. 
  18. Novel probes for studying treatment of CNS-based lysosomal storage diseases. NIH R01 HD076004-01, PI:  Scott D Larsen, Co-I: Duxin Sun. 2013-2016.  
  19. Investigation of inequivalence of buproprion hydrochloride extended release tablets: In vitro metabolism quantification. FDA HHSF223201310183C, PI: Duxin Sun. 2013-2015.    
  20. Mechanisms of motor neuron toxicity in Kennedy disease. NIH R01 NS055746-06A1, PI: Andrew Lieberman, Co-I: Duxin Sun. 2012-2017. 
  21. Development of novel anti-leukemia agents targeting the menin-MLL interaction. NIH R01 CA160467-01. PI: Jolanta Grembecka, Co-I: Duxin Sun. 2011-2016. 
  22. DUB Inhibitors for Treatment of B-cell Malignancies. Lymphoma and Leukemia Society. PI: Nick Donato, Co-I: Duxin Sun. 2012-2013. 
  23. Potent and Highly Selective D3 Ligands for the Treatment of Cocaine Abuse. NIH R01 DA032943. PI: Shaomeng Wang, Co-I: Duxin Sun. 2012-2016. 
  24. In vivo proof of efficacy studies for a novel glucosylceramide synthase inhibitor with central nervous system activity. NIH R21 NS079633-01, PI: James Shayman, Co-I: Duxin Sun. 2012-2014.
  25. Receptor Na/K-ATPase antagonists as novel therapeutics for renal/cardiac diseases. NIH R01 HL109015-01. PI: ZiJian Xie, Co-I: Duxin Sun. 2011-2015. 
  26. Menin-MLL Fusion Inhibitor Program. Lymphoma and Leukemia Society. UM347450 /N013134-03. PI: Jolanta Grembecka,  Co-I: Duxin Sun. 2010-2015. 
  27. Chaperones and Small Molecules NIH R01 NS059690-S1, PI: Jason Gestwicki, Co-I: Duxin Sun. 2010-2011. 
Supported Patents
  1. Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jay L. Hess, Duxin Sun, Xiaoqin Li. Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof.

US patent number 9216693 issued 12/22/2015.

US patent application 14/773,686 filed 9/8/2015. 

US patent application 14/937421 filed 11/10/2015.

  1. Shaomeng Wang, Jianfang Chen, Donna McEachern, Longchuan Bai, Liu Liu, Duxin Sun, Xiaoqin Li, Angelo Aguilar. BCL-2/BCL-XL Inhibitors and therapeutic methods using the same.

US patent number 9096625 issued 7/15/2015.

US patent application 14/816,191 filed 8/3/2015.

  1. Shaomeng Wang, Haibin Zhou, Jianfang Chen, Angelo Aguilar, Jennifer Meagher, Duxin Sun, Chao-Yie Yang, Liu Liu, Longchuan Bai, Donna J. McEachern, Jeanne A. Stuckey-Cupp, Xiaoqin Li. BCL-2/BCL-XL Inhibitors and therapeutic methods using the same.

US patent number 8691184 issued 4/8/2014.

  1. Shaomeng Wang, Shanghai Yu, Wei Sun, Sanjeev Kumar Shangary, Duxin Sun, Peng Zou, Donna McEachern, Yujun Zhao. Spiro-oxindole MDM2 antagonists.

US patent number 9079913 issued 6/24/2015.

US patent number 8877796 issued 11/4/2014.

US patent number 8518984 issued 8/27/2013. 

  1. Ruijuan Luo, Duxin Sun, Jamie Connarn, Vicki L. Ellingrod, Melvin McInnis. Bupropion metabolites and uses thereof

Filed for US provisional patent 3/31/2016.

  1. Scott D. Larsen, Akira Abe, Liming Shu, Michael W. Wilson, Richard F. Keep, Duxin Sun, James A. Shayman. Glycosylceramide synthase inhibitors and therapeutic methods using the same.

Filed for US provisional patent 2015.

  1. Shaomeng Wang, Yujun Zhao, Bing Zhao, Angelo Aguilar, Liu Liu, Longchuan Bai, Donna McEachern, Duxin Sun, Bo Wen, Ruijuan Luo, Ting Zhao, Arul Chinnaiyan, Irfan A. Asangani, Jeanne Stuckey, Jennifer Lynn Meagher, and Xu Ran. 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors.

Filed for US provisional patent 2014; US patent application 14/633,360 filed 2/27/2015.

  1. Shaomeng Wang, Arul Chinnaiyan, Irfan Asangani, Yujun Zhao, Bing Zhou, Liu Liu, Longchuan Bai, Angelo Aguilar, Donna J. McEachern, Xu Ran, Duxin Sun, Chao-Yie Yang, Ruijuan Luo, Jeanne A. Stuckey, Jennifer Meagher, Xiaoqin Li, Bo Wen, Hacer Karatas, Ting Zhao. BET bromodomain inhibitors and therapeutic methods using the same.

PCT patent application PCT/US2014/022953 filed 3/11/2014.

 

Listing Row

Tuesday, September 10, 2013
Tuesday, September 10, 2013